Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C.

J Biol Chem 2009 May 26;284(22):15215-23. Epub 2009 Mar 26.

Department of Pharmacology and Biomedical Sciences Graduate Program, University of California at San Diego, La Jolla, California 92093-0721, USA.

PHLPP2 (PH domain leucine-rich repeat protein phosphatase 2) terminates Akt and protein kinase C (PKC) activity by specifically dephosphorylating these kinases at a key regulatory site, the hydrophobic motif (Ser-473 in Akt1). Here we identify a polymorphism that results in an amino acid change from a Leu to Ser at codon 1016 in the phosphatase domain of PHLPP2, which reduces phosphatase activity toward Akt both in vitro and in cells, in turn resulting in reduced apoptosis. Depletion of endogenous PHLPP2 variants in breast cancer cells revealed the Ser-1016 variant is less functional toward both Akt and PKC. In pair-matched high grade breast cancer samples we observed retention of only the Ser allele from heterozygous patients (identical results were observed in a pair-matched normal and tumor cell line). Thus, we have identified a functional polymorphism that impairs the activity of PHLPP2 and correlates with elevated Akt phosphorylation and increased PKC levels.

Download full-text PDF

Source
http://newtonlab.ucsd.edu/documents/Brognardetal.2009.pdf
Web Search
http://www.jbc.org/cgi/doi/10.1074/jbc.M901468200
Publisher Site
http://dx.doi.org/10.1074/jbc.M901468200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685702PMC
May 2009
16 Reads

Publication Analysis

Top Keywords

protein kinase
8
breast cancer
8
akt protein
8
akt
5
phlpp2
5
samples observed
4
codon 1016
4
observed retention
4
leu ser
4
ser codon
4
1016 phosphatase
4
reduces phosphatase
4
phlpp2 reduces
4
domain phlpp2
4
phosphatase domain
4
retention ser
4
change leu
4
amino acid
4
heterozygous patients
4
polymorphism amino
4

References

(Supplied by CrossRef)

Mol. Cell Biol. 1994

Cancer Res. 2001

Similar Publications